Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.09.2023 | News item

Bosutinib-related risk of interstitial lung disease

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency has recommended updating product information for bosutinib to include the risk of interstitial lung disease (ILD), according to a report published in the WHO Pharmaceuticals Newsletter . …
Metadaten
Titel
Bosutinib-related risk of interstitial lung disease
Publikationsdatum
01.09.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-45729-4

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

BBIBP-CorV